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Introduction
Stem cells possess tremendous potential for cellular and gene therapies of many human diseases. Efficient gene transfer into hematopoietic progenitor cells (HPC), derived from the bone marrow (BM), mobilized peripheral blood (mPB) or cord blood (CB), could provide valuable therapies for genetic deficiencies, as well as for cancer and infectious diseases such as HIV. Reported retroviral transduction efficiencies into CD34 + progenitors range from 10% to 60%, and greater than 75% in the NOD-SCID
human HPC engraftment mouse model [1] [2] [3] [4] [5] [6] [7] [8] . Many factors contribute to the range in CD34 + cell transduction including the elements in the vector, the source of cells, the culture conditions and timing of vector addition, and notably the quality and purity of the vector.
Investigators have used the method of high-speed centrifugation to increase vector titers to achieve higher transduction efficiencies. In contrast, our vector is purified by size exclusion chromatography instead of centrifugation to ensure vector safety and purity for human use, since column purification allows sterile filtering without significantly reducing vector titers 9, 10 . We sought to optimize lentiviral vector transduction into CD34 + progenitors using materials and methods that are clinically relevant.
The ATP-binding cassette (ABC) transporter family of proteins is well characterized for its ability to efflux a wide range of lipophilic, and structurally unrelated small molecules and drugs, particularly chemotherapeutic agents and HIV protease inhibitors 11, 12 . There are compelling data suggesting the functional importance of ABC transporters in the biology of hematopoietic stem cells [13] [14] [15] [16] [17] [18] [19] [20] . We theorized that the high levels of ABC transporter expression may in part contribute to the lower transduction efficiency obtained in primitive hematopoietic cells, and that an ABC transporter inhibitor may increase CD34 + progenitor transduction efficiency.
High reproducible transduction efficiencies are paramount for therapeutic success of stem cell gene therapy. We present here that ABC transporter substrate inhibitors increase transduction of VSV-G pseudotyped lentiviral vectors in CD34 + progenitor cells, and we investigate the mechanism for this phenomenon. The data describe a clinically applicable approach for ensuring efficient lentivirus vector transduction into hematopoetic progenitor cells, with implications for efficient gene delivery for treatment of genetic and infectious disease.
Methods
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Reagents
Verapamil (V4629), diltiazem (D2521), probenecid (P8761), quinidine (Q0875), sodium orthovanadate (S6508), alpha-tocopherol (T3251), arsenic trioxide (A1010) and reserpine (R0875) were purchased from Sigma Aldrich (Bedford, MA) as USP grade reagents when available. Ritonavir (Norvir) was obtained from Abbott Laboratories (Abbott Park, IL).
Protamine sulfate (P4505) and polybrene (H2968) were purchased from Sigma.
The anti-TGF antibody (clone AB-100-NA) was purchased from R&D Systems (Minneapolis, MN).
Vector production
VRX494 is a safety modified, gutted HIV vector that expresses the eGFP cDNA from the endogenous HIV LTR. The clinical trial lentivector VRX496 is identical to VRX494, except that it does not encode eGFP, but instead a 186-base truncated tag region derived from eGFP. Vector was produced by calcium phosphate-mediated transfection of two plasmids: the vector construct and the helper construct, VIRPAC, which produce higher titers than a three-plasmid system. This vector production system has been meticulously designed for safety to avoid generation of a replication competent lentivirus (RCL) 21 . Laboratory scale, or high-speed centrifuged vector, was produced by calcium phosphate mediated transfection of vector plasmid with a VSV-G containing packaging construct into 293 cells. Supernatant was collected every 12 hours from 24 to 48 hours after transfection, pooled, then concentrated by high-speed centrifugation at 10,000 rpm for 12 hours.
The vector was resuspended in storage buffer at approximately 1/400 of its original volume, and then frozen at -80°C. The titer of the centrifuged vector was determined by the frequency of GFP expression on HeLa-tat cells and was found to range between 1 x 10 9 to 5 x 10 9 transducing units (TU) per ml.
A scalable purification process was developed for clinical or manufacturing-grade vector. Supernatant of plasmid transfected 293 cells was harvested at 24, 36, and 48 hours after transfection. The supernatant was filtered through a series of cartridge filters of decreasing pore diameter down to 0.22 µm, then concentrated by ultrafiltration. Buffer was exchanged and benzonase was added to destroy contaminating plasmid and cellular DNA. The vector was then purified by size exclusion chromatography and formulated in storage buffer 9 . The final vector preparation was sterilized by filtration through a 0.22 µm cartridge filter. Vector titers were determined by TaqMan PCR for . Final vector titers achieved were greater than 10 8 TU per ml.
Cells
Frozen CD34 + progenitors (greater than 98% purity) derived from adult bone marrow, adult G-CSF mobilized peripheral blood, and cord blood were purchased from AllCells (Berkeley, CA) under an IRB-approved protocol. Additional peripheral blood CD34 + cells mobilized by cyclophosphamide and G-CSF were generous gifts from Dr.
Christian Chabannon (Cellular Therapy Institute, Cancer Center, Marseilles, France).
Rhesus macaque CD34+ cells derived from bone marrow were kindly provided by Dr.
Boris Camels (NIH, Bethesda, Maryland). 22, 23 . T cells were transduced with 10 TU per cell of VRX494 in the presence or absence of 5 to 50 µM ritonavir or 10 to 50 µg/mL verapamil.
Transduction
PBMC were transduced such that vector comprised 5% of the medium in the presence or absence of 0.5 to 1 mM probenecid or 10 to 50 µg/mL verapamil. Cells were washed 24 hours after drug addition to remove the drugs, followed by a second addition of vector at the same dose. . This method yielded transduction levels of 22% to 50% in CB, 10% to 32% in mPB, and 15% to 22% in BM (Figure 2A ).
Transduction in primary cells and non-hematopoietic stem cell progenitors

CD34 transduction using column purified VRX494
Expression of eGFP stabilized between day 7 and 11, similar to a pattern observed
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. LTC-IC were transduced at the same frequency as more committed progenitors as defined by primary CFU.
A number of strategies including spinoculation, sequential vector additions, cytokine prestimulation, absence of cytokine co-stimulation, use of serum substitutes, use of polybrene and protamine sulfate, and use of a TGF-antibody to modulate cell cycle, were directly compared in attempts to increase CD34 + cell transduction efficiency.
However, these approaches resulted in only marginal increases ranging from 2 to 10% above baseline (data not shown).
The ABC transporter inhibitor, verapamil, improves lentivector transduction in hematopoietic progenitor cells. There were no differences in total CFU production in the absence or presence of verapamil (142 +/-39 vs. 187 +/-51 total CFU per 1000 cells plated, respectively). In the absence of drug, our culture conditions produced an approximate 1:2 ratio of BFU-E to CFU-GM. However after verapamil exposure, the ratio changed to 4:1. Because total CFU counts were not altered, verapamil does not appear to be selectively toxic to CFU.
Verapamil resulted in a dose dependent decrease in cellular viability and total cell numbers, although the severity of the decrease was highly variable between experiments ( Figure 2E ). At 4 days post-transduction, the total cell number was reduced by 2 to 3-fold compared to cells transduced in the absence of verapamil. Verapamil exerted slighlty less toxicity toward CB than against BM or mPB derived cells. were observed between primary and secondary transplant ( Figure 3B and Table 1 ). An There was dose dependent toxicity observed with all drugs tested; viability fell to 43% to 85% relative to non-drug treated controls (Table 2) . Likewise, the expansion of cells was reduced up to 2-fold in the presence of these drugs compared to transduction in the absence of drugs. CD34 + progenitors differentiate during culture in cytokines and the proportion of cells expressing the CD34 antigen decreases over time. After 7 days, the proportion of cells remaining CD34 + was similar for all conditions tested, and similar CFU counts were measured among the different drug conditions. This indicates that at this level of culture, no drug-mediated selection could be detected.
Verapamil improves transduction of primary and secondary SCID-repopulating cells
Combinations of functionally dissimilar ABC transporter substrates were cocultured to determine whether transduction levels could be improved synergistically.
Near complete cytotoxicity was observed when two substrates were co-cultured at the conventional dose used in the experiments mentioned above. Reduced cytotoxicity was observed when two substrates were co-cultured at half their conventional doses, but transduction efficiencies were similar to the level obtained using a single substrate at its conventional dose. This suggests an additive but not synergistic effect during co-culture of functionally dissimilar ABC transporter substrates (Table 2) .
Structurally diverse ABC transporter substrates increase transduction of human NOD-SCID repopulating cells
To test whether additional ABC transporter substrates similarly improve SRC transduction, NOD-SCID mice were transplanted with 2 x 10 5 cord blood CD34 + progenitors that had been transduced with clinical grade VRX494 without ABC transporter substrates (n=14) or in the presence of verapamil (n=13), quinidine (n=4),
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Cells recovered from bone marrow were tested for eGFP expression among cells expressing CD45, CD34, CD33, or CD19. As evident from Table 3 , the assay has inherent variability between mice within a single cohort. Expression of eGFP was observed in an average of 47% of CD45 + cells recovered from mice in the control group and 76% for verapamil, 60% for quinidine, 65% for diltiazem and 52% for ritonavir ( Figure 5 , Table 3 ). Cells transduced in the presence of ABC transporter substrates exhibited higher SRC transduction. In particular, verapamil, diltiazem, and ritonavir caused the greatest increases in transduction in CD19 + cells compared to no drug controls. Further, increased median CD45 + cell transduction was observed for all drugs compared to the control. The proportion of each lineage was similar when transduced in the presence or absence of ABC transporter substrates. These data suggest that SRC are transduced at a higher rate in the presence of ABC transporter substrates, with no apparent toxicity toward subsequent repopulation potential.
ABC transporter substrates do not improve transduction in every cell type
We were interested if this phenomenon was hematopoietic progenitor-specific. In the presence of verapamil, transduction was improved for VSV-G pseudotyped vectors. In contrast, RD114 pseudotyped vector transduction was entirely unaffected.
These data provide suggestive evidence that enhancement of transduction in hematopoietic cells with lentivirus vectors is specific to the cell biology and the vector envelope.
Discussion
We describe in this report a novel approach for improving lentiviral gene transfer into human hematopoietic progenitors by exposing cells to verapamil during transduction. Relative to cells transduced under standard conditions, verapamil increased transduction efficiencies 2 to 6-fold resulting in stable transduction levels of 80%-90% in cells recovered from primary and secondary transplant in NOD/SCID mice.
Other ABC transporter inhibitor substrates also improved transduction but less efficiently than verapamil, and non-substrate inhibitors showed no effect.
Importantly, clinically relevant vector used to attain this high level of transduction was column purified and not centrifuged. High-speed centrifugation has been a method for concentrating vector in order to achieve higher transduction efficiencies reported elsewhere. High-speed centrifugation does not result in a clinically applicable vector since it cannot be sterile filtered, which is a necessary step to ensure sterility prior to use in humans. Therefore, we report for the first time high lentiviral transduction efficiencies in CD34 + hematopoietic progenitor cells using a grade of vector that is clinically applicable.
Verapamil is a clinically approved drug, used for the treatment of arrhythmia, We present a lentivirus-based vector acceptable for use for human gene therapy, which efficiently transduces stem cells resulting in stable gene expression before and after differentiation in vivo. We further describe a novel approach for increasing transduction efficiencies into these cells, which reduces the amount of vector necessary for efficient transduction, and provides a useful tool for future therapeutic stem cell clinical trials. 
